Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant-Reference-Cited by-同舟云学术

Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

Published:2022-01-17 Issue:4 Volume:78 Page:613-621
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Hibino Hideyuki,Sakiyama Naomi,Makino Yoshinori,Makihara-Ando Reiko,Horinouchi Hidehito,Fujiwara Yutaka,Kanda Shintaro,Goto Yasushi,Yoshida Tatsuya,Okuma Yusuke,Shinno Yuki,Murakami Shuji,Hashimoto Hironobu,Akiyoshi Takeshi,Imaoka Ayuko,Ohe Yuichiro,Yamaguchi Masakazu,Ohtani Hisakazu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-022-03275-5.pdf

Reference35 articles.

1. Aapro M, Gralla RJ, Herrstedt J, Molassiotis A, Roila F (2016) MASCC/ESMO Antiemetic Guidelines. Ver 1:2

2. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97(9):2290–2300. https://doi.org/10.1002/cncr.11320

3. Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63(1):75–83. https://doi.org/10.1007/s00280-008-0713-y

4. Hibino H, Makino Y, Sakiyama N, Makihara-Ando R, Hashimoto H, Akiyoshi T, Imaoka A, Fujiwara Y, Ohe Y, Yamaguchi M, Ohtani H (2021) Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient. Int J Clin Pharmacol Ther 59(4):328. https://doi.org/10.5414/CP203758

5. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44(3):215–223. https://doi.org/10.1177/0091270003262950

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism;Yonago Acta Medica;2024

2. Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration;Journal of Pharmaceutical Health Care and Sciences;2023-12-04

3. Adjustment of Dosage Regimen in: Renal Impairment, Liver disease and Pregnancy;Handbook of Pharmacokinetics and Toxicokinetics;2023-07-03

4. Design and conduct considerations for studies in patients with hepatic impairment;Clinical and Translational Science;2022-10-09